U.S. Markets close in 5 hrs 42 mins

OraSure Technologies, Inc. (OSUR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.16-0.01 (-0.08%)
As of 10:18AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close12.17
Open12.28
Bid12.21 x 800
Ask12.26 x 1100
Day's Range12.01 - 12.59
52 Week Range5.23 - 19.75
Volume91,854
Avg. Volume2,225,498
Market Cap870.15M
Beta (5Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)-0.04
Earnings DateNov 04, 2020 - Nov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.86
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-41% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    OraSure’s ORAcollect®·RNA Device Included in EUA Granted to Quadrant Biosciences Inc. for COVID-19 Test

    BETHLEHEM, Pa., Sept. 24, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its ORAcollect®·RNA (OR-100) saliva collection device has been included in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) granted to Quadrant Biosciences Inc. for a COVID-19 laboratory test. Under the EUA, the ORAcollect®·RNA (OR-100) device can be used to collect saliva samples from individuals suspected of COVID-19 infection by a healthcare professional. This is the sixth EUA to include a collection device from the Company’s DNA Genotek subsidiary and the first to exclusively utilize a saliva collection method. Quadrant’s Clarifi COVID-19 Test Kit, developed in partnership with SUNY Upstate Medical University, leverages the company’s established expertise in RNA-based diagnostics. The non-invasive, and easy to administer, saliva swab test determines the presence or absence of SARS-CoV-2 viral RNA, and will be immediately available for use by high-complexity clinical laboratories serving patients through physicians' offices, urgent care clinics and hospitals.“Expansion of testing is a key to helping slow the spread of COVID-19 and safely reopen economies. That’s why DNA Genotek is leveraging our expertise in non-invasive sample collection to provide more devices to more testing facilities, to help check millions of people around the world for COVID-19,” said Kathleen Weber, Executive Vice President, Business Unit Leader, Molecular Solutions at DNA Genotek. “DNA Genotek, now with six EUAs that include our collection kits, has emerged as a leading company helping to detect the virus.”“We are thrilled that the FDA has issued the Clarifi COVID-19 test EUA approval for use in the diagnosis of COVID-19,” said Richard Uhlig, Founder and CEO of Quadrant Biosciences. “The coronavirus has had a devastating effect on health and welfare worldwide, so it is extremely gratifying for us to take the expertise we have gained working on RNA diagnostic tests for other health conditions, such as autism spectrum disorder and Parkinson's disease, and apply that expertise to the development of this critically important test.”About OraSure Technologies OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, CoreBiome (now operating under the Diversigen brand), UrSure and Novosanis, OraSure provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.About DNA Genotek DNA Genotek Inc., a subsidiary of OraSure Technologies, Inc., focuses on providing high-quality biological sample collection products and end-to-end services for human genomics and microbiome applications. The Company's Oragene®•Dx and ORAcollect®•Dx product lines are the first and only FDA 510(k) cleared saliva-based DNA collection devices for in vitro diagnostic use. DNA Genotek also offers Research Use Only products to collect and preserve large amounts of DNA or RNA from multiple sample types. DNA Genotek markets its products worldwide and has a global customer base with thousands of customers in over 100 countries. For more information about DNA Genotek, visit www.dnagenotek.com Important Information This press release contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: ability to successfully manage and integrate acquisitions of other companies in a manner that complements or leverages our existing business, or otherwise expands or enhances our portfolio of products and our end-to-end service offerings, and the diversion of management’s attention from our ongoing business and regular business responsibilities to effect such integration; the expected economic benefits of acquisitions (and increased returns for our stockholders), including that the anticipated synergies, revenue enhancement strategies and other benefits from the acquisitions may not be fully realized or may take longer to realize than expected and our actual integration costs may exceed our estimates; impact of increased or different risks arising from the acquisition of companies located in foreign countries; ability to market and sell products, whether through our internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the U.S. Food and Drug Administration (“FDA”) or other regulators; the impact of the novel coronavirus (“COVID-19”) pandemic on our business and our ability to successfully develop new products, validate the expanded use of existing collector products and commercialize such products for COVID-19 testing; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for the Company’s products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales; ability to identify, complete, integrate and realize the full benefits of future acquisitions; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention (“CDC”) or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2019, Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.Investor Contact: Sam Martin Argot Partners 212-602-1902 orasure@argotpartners.com Media Contact: Jeanne Mell VP Corporate Communications 484-353-1575 media@orasure.com

  • GlobeNewswire

    Former CEO of H2O+ Beauty, Former Chief Chemist of MAC Cosmetics Launch Innovative Skincare Brand Using First-Ever Scientific Microbiome Testing

    Pure Culture Beauty delivers a clean, customized skincare regimen formulated to enhance consumers’ skin healthSAN FRANCISCO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Today, Joy Chen, former CEO of H2O+ Beauty, and Victor Casale, former Chief Chemist of MAC Cosmetics and co-founder of CoverFX, announced the launch of Pure Culture Beauty, the first skincare brand using data and science to deliver a comprehensive, customized skincare regimen to consumers. Pure Culture Beauty is taking an innovative approach to skincare, offering a suite of personalized skincare products that are uniquely developed to target the individual’s skin microbiome and improve the skin’s overall health. “We are thrilled to announce the launch of Pure Culture Beauty and unveil our customized approach to skincare,” said Chen, co-Founder and CEO of Pure Culture Beauty. “We know skincare is personal and that the products you use should reflect your particular skin needs; yet, most people don’t understand their skin type and health, which leads them to choose products that aren’t the best fit. With this launch, we’re empowering consumers to gain a deep understanding of their skin and offering a skincare routine that’s just right for them.”The products – a cleanser, serum, and moisturizer – utilize clean, active ingredients that are meant to work as a system to enhance the skin’s microbiome. Each of the gender-neutral products has a custom formula designed to meet the unique skin needs of the users.“We know personalization exists in nearly all facets of our lives, but it tends to stop at skincare. While consumers can choose what products to use or what brands to buy, they rarely have any say in the product formulation used to address their skin - what’s inside the bottle is the same for everyone,” said Casale, co-Founder and Chairman of Pure Culture Beauty. “Pure Culture Beauty is different: we’re developing products that start with the individual and end with targeted, personalized skincare delivered right to your home. We’re very excited to finally launch.”Pure Culture Beauty has partnered with DNA Genotek and Diversigen, the leading providers of high-quality biological sample collection products and end-to-end services for genomics and microbiome applications. DNA Genotek will supply the OMNIgene·SKIN microbiome collection kits and Diversigen will provide full microbiome analysis services, offering a complete understanding of the users’ skin microbiome. DNA Genotek and Diversigen are wholly owned subsidiaries of OraSure Technologies, Inc. (NASDAQ: OSUR). “Through our combined deep understanding of science and emerging research, DNA Genotek and Diversigen recognize the importance of understanding the individual’s skin microbiome to help companies like Pure Culture Beauty provide a personalized offering,” said Dan Knights, PhD, Senior Scientific Advisor, Diversigen Inc. “Bringing together the highly complementary capabilities of DNA Genotek’s OMNIgene·SKIN microbiome collection kits and Diversigen’s analytical services will advance Pure Culture Beauty’s vision of using this powerful technology to provide their customers with personalized skincare options. We are thrilled Pure Culture Beauty has selected DNA Genotek and Diversigen’s sample-to-insight solutions.”About Pure Culture Beauty At Pure Culture Beauty, we deliver pure products for the culture of your skin. Our company, founded by Joy Chen and Victor Casale, was launched with a bold vision for the beauty industry: to deliver personalized skincare products that are just right for you. Using the results of our skin profile analysis, At-Home Skin Test as well as the first-to-market Skin Microbiome Kit, we deliver customized solutions straight to your doorstep. Our gender-neutral products were designed to work as a system, formulated with clean, active ingredients to enhance your skin’s overall health. So, as your skin changes, so do the products we make for you. Pure Culture Beauty is headquartered in San Francisco, CA. For more information, please visit PureCultureBeauty.com.Media contact: Lexy Siegel LSiegel@GroupGordon.com (212) 784-5727

  • GlobeNewswire

    OraSure’s ORAcollect®·RNA Device Included in EUA Granted to MiraDx Inc. for SARS-CoV-2 Test

    BETHLEHEM, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its ORAcollect®·RNA (OR-100) collection device was included along with other devices in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) granted to MiraDx Inc., a Los Angeles-based molecular genetics company. This is the fifth EUA to include a collection device from the company’s DNA Genotek subsidiary. MiraDx will utilize ORAcollect®·RNA to collect oropharyngeal samples in their COVID-19 testing program for essential workers and first responders to help slow, and hopefully prevent, the spread of COVID-19. Samples are collected under the supervision of a healthcare professional.MiraDx is performing COVID-19 PCR-based viral detection testing in their CLIA-certified, high-complexity molecular diagnostics laboratory that can provide 24-48 hour turnaround time. The MiraDx SARS-CoV-2 assay, combined with ORAcollect®·RNA, facilitates the detection of nucleic acid from SARS-CoV-2 using highly sensitive quantitative PCR technology.“There’s an urgent need for COVID-19 testing so that people who are infected can be easily and quickly identified,” said Joanne Weidhaas, Founder, MiraDx Inc. "Reliable, high-quality testing is essential to help healthcare systems overcome this pandemic. We are focused on delivering the highest quality, most sensitive and dependable testing possible.”“Making rapid and accurate diagnostic tools available is critical for early detection and control of COVID-19," said Kathleen Weber, Executive Vice-President, Business Unit Leader, Molecular Solutions at DNA Genotek. “Our global leadership in molecular collection devices has enabled MiraDx to utilize a highly accurate collection device to detect genetic material from SARS-CoV-2. With our legacy of innovation and unique capabilities in molecular diagnostics, we’re in a strong position to help provide a diagnostic tool for the COVID-19 public health challenge.”MiraDx was spun out of Yale University in 2009 by scientists and clinicians seeking advances in the field of personalized medicine and treatment based on microRNA-based genetic testing. About OraSure Technologies OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, CoreBiome (now operating under the Diversigen brand), UrSure and Novosanis, OraSure provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.About DNA Genotek DNA Genotek Inc., a subsidiary of OraSure Technologies, Inc., focuses on providing high-quality biological sample collection products and end-to-end services for human genomics and microbiome applications. The Company's Oragene®•Dx and ORAcollect®•Dx product lines are the first and only FDA 510(k) cleared saliva-based DNA collection devices for in vitro diagnostic use. DNA Genotek also offers Research Use Only products to collect and preserve large amounts of DNA or RNA from multiple sample types. DNA Genotek markets its products worldwide and has a global customer base with thousands of customers in over 100 countries. For more information about DNA Genotek, visit www.dnagenotek.com.    Investor Contact: Sam Martin  Argot Partners   212-602-1902  orasure@argotpartners.comMedia Contact:  Jeanne Mell VP Corporate Communications 484-353-1575 media@orasure.com